Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib

Virginia G. Kaklamani*, Kalliopi Siziopikou, Denise Scholtens, Mario Lacouture, Jennifer Gordon, Regina Uthe, Caitlin Meservey, Nora Hansen, Seema A. Khan, Jacqueline S. Jeruss, Kevin Bethke, Mary Cianfrocca, Steven Rosen, Jamie Von Roenn, Jeffrey Wayne, Vamsi Parimi, Borko Jovanovic, William Gradishar

*Corresponding author for this work

Research output: Contribution to journalArticle

21 Scopus citations

Abstract

Lapatinib, a dual kinase inhibitor against epidermal growth factor receptor (EGFR) and human epidermal receptor two (HER2) has shown efficacy in treating HER2 positive breast cancer. Nanoparticle albumin bound (nab) paclitaxel was developed to reduce toxicities from paclitaxel and improve its efficacy. Thirty patients with stage I-III HER2 positive breast cancer were treated in the neoadjuvant setting with lapatinib 1,000 mg/day and nabpaclitaxel 260 mg/m2 every 3 weeks for four cycles. The primary end point of the trial was clinical response rate (cRR) with secondary end points including pathologic complete response rate (pCR), tolerability of the combination, and marker response. The cRR was 82.8% (24 patients) with six (20.7%) patients having complete clinical response, 18 (62.1%) having partial clinical response, and five (17.2%) stable disease. A pCR was observed in five of the 28 patients (17.9%). The most frequent grade 2 toxicities were neuropathy in nine patients (30%), fatigue in seven patients (23.3%), rash in 11 patients (36.7%), and bone pain in 10 patients (33.3%). There was no significant drop in the left ventricular ejection fraction (LVEF). Of the tissue markers examined, we were not able to find a predictor of response. The combination of lapatinib and nabpaclitaxel was well tolerated and provided good efficacy in women with HER2 positive breast cancer. This combination offers an alternative non-anthracycline-containing regimen for women with HER2 positive breast cancer.

Original languageEnglish (US)
Pages (from-to)833-842
Number of pages10
JournalBreast Cancer Research and Treatment
Volume132
Issue number3
DOIs
StatePublished - Apr 1 2012

    Fingerprint

Keywords

  • Breast cancer
  • HER2
  • Lapatinib
  • Nab-paclitaxel
  • Neoadjuvant therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this